Martin Shkreli

1. THE FACT: The speaker states, "we bought a photonic/optical computing stock: $QCLS. i'm convinced that the answer to frontier computing is optical, not quantum. we're calling it 'quantum class' so investors understand it. $100 is my near-term target." 2. THE BRIDGE: The speaker has made a direct investment in QCLS, believes optical computing is the future of frontier computing over quantum, and has a specific, aggressive near-term price target of $100. This indicates strong conviction and a clear bullish outlook. 3. THE VERDICT: Long QCLS based on the speaker's conviction that optical computing is the future, their personal investment, and a near-term price target of $100.

Short CAPR; Shkreli explicitly labels the company a complete fraud, implying terminal structural impairment beyond valuation criticism, though no specific mechanism is stated and no personal short position is disclosed.

1. THE FACT: Martin Shkreli states that "quantum will continue to sink as $NVDA buys Groq, showing no interest in QC." He also states "the need for compute is still real. i think we have to think about a path past transistor-based computing, or we will actually cover the world (and space?) in data centers". 2. THE BRIDGE: NVDA's acquisition of Groq, a company focused on AI inference chips, indicates a strategic move to strengthen its position in the high-performance computing and AI sector, rather than quantum computing. This suggests NVDA is doubling down on a proven and growing market (AI/compute) where demand is "still real," while Shkreli believes quantum computing will "sink." 3. THE VERDICT: NVDA is making strategic acquisitions to solidify its leadership in the high-demand compute sector, specifically AI, which is a positive indicator for its continued growth.

Short HIMS on the basis that its peptide-based product lines (likely compounded GLP-1/semaglutide offerings) lack legitimate medical efficacy — author argues the core growth driver is scientifically unfounded, implying structural revenue risk if regulatory or clinical scrutiny intensifies.

Buy RDDT into the rumor-driven selloff linked to GOOGL; Shkreli expresses personal conviction at current levels and is conducting an expert call with a former RDDT executive, suggesting fundamental due diligence supports the bullish view.

Short CPHI as fair value is $0.10, implying extreme overvaluation and expected decline.

Short AGEN; a recent PIPE financing fails to alter the company's fundamentally weak outlook, and the stock should revert to the PIPE offering price, implying meaningful downside from current levels.

Short JLHL; Shkreli discloses an active short position, citing CEO Jiaqi Hu's control of BJIDE — a related party accounting for 53% of revenue — as a structural red flag consistent with a pump-and-dump scheme now in the dump phase.

Buy EVMN on the dip following a drug failure, as the overhang clears and market attention can now re-rate the IL-18 program, a potentially differentiated asset in the autoimmune space.

Buy BCRX as it trades at a steep discount to sum-of-parts value (~$10 vs. $30 target); navenibart positions the company as a dominant player in hereditary angioedema (HAE), a high-value rare disease market.

Short GSK because the high level of competition in the pharmaceutical industry makes it statistically improbable for GSK to exclusively develop a cure for asthma, negating a potential source of future upside.

The author alleges STRC is committing securities fraud through misleading advertising, implying the stock is overvalued and should be shorted.

Short Canopy Growth as its income statement is exceptionally poor, indicating severe fundamental weakness in the business.

The author, a known pharma expert, strongly defends the legitimacy and highlights the significant late-stage (Phase 3) trial status of Eli Lilly's drug Retatrutide, implying a bullish outlook on its prospects.

The speaker would short TAO, implying that its lack of recognition among informed participants suggests it is likely an overhyped or insignificant asset.